SLC5A2 and chronic kidney disease: Two of the four clinical trials of SGLT-2 inhibition conducted in people with CKD have enrolled people without diabetes (DAPA-CKD and EMPA-KIDNEY), and in both trials SGLT-2 inhibition has been continued below an eGFR of 20 mL/min/1.73m2 without evidence of increased adverse events [1, 3].